Objectives. The aim of this study is to determine the factor changing the hepatic 20 disposition of a drug during hypothermia using rat liver perfusion system. 21
INTRODUCTION 41
Hypothermia is a therapeutic strategy used after cerebral ischemia and cardiac 42 arrest to protect the brain.
Although several clinical studies have reported that 43 treatment with hypothermia in patients with severe head injury, acute stroke, or hastened 44 neurologic recovery improved the outcome (1-3), therapeutic hypothermia can have side 45 effects such as arrhythmia, blood coagulation problems, and impaired immune function 46 (4). Several medicines such as anti-arrhythmic or antibiotics are administered to 47 negate these effects.
Furthermore, alterations in the drug disposition of midazolam 48 (5) and phenytoin (6,7) under hypothermia have been reported from clinical studies. 49
However, there has been little systematic information concerning changes in the 50 pharmacokinetics of drugs during hypothermia. 51
In this study, we defined 32 and 28 o C as hypothermia. Because therapeutic 52 hypothermia is done at 32-34 o C, it is useful to know the alternation of hepatic 53 disposition of drugs at 32 o C.
Moreover, we examined the change of hepatic 54 disposition at 28 °C, aiming to consider the unexpected conditions such as too much 55 cooling and body temperature dependency on pharmacokinetic change of a drug in the 56 patients fully by three different body temperatures. 57
We have already reported that the pharmacokinetics of phenolsulfonphthalein 58 (PSP), indocyanine green (ICG) and fluorescein isothiocyanate-dextran (FD-4, Mw 59 4400) changed under hypothermic conditions in rats (8). However, as many factors 60 affect drug disposition such as blood flow, transporter and drug metabolizing enzyme, it 61 is difficult to determine individual factors in studies in vivo.
It is necessary to 62 determine the individual factors affecting drug disposition for prediction the 63 pharmacokinetics during hypothermia.
Generally, the hepatic disposition of drugs 64 consists of four steps (i) uptake into liver from blood, (ii) efflux from the liver, (iii) 65 elimination by metabolism and (iv) excretion into bile from liver.
Under the 66 hypothermia, the activity of several transporters and enzymes could changed and this 67 alternation affects on the hepatic disposition of drugs.
In this study, we tried to 68 evaluate the effect of hypothermia on hepatic disposition by isolated liver perfusion. 69
The isolated liver is often used to explore hepatic physiology and pathophysiology, 70 because it is easy to control the flow rate and temperature of the perfusate. 71
We chose PSP, ICG and FD-4 as model compound and these compounds 72 eliminate by different process. PSP is conjugated by enzymes and excreted into bile 73 via multidrug resistance associated protein2 (Mrp2), while ICG is excreted via 74 multidrug resistance P-glycoprotein2 (Mdr2).
On the other hand, FD-4 is eliminated 75 by glomerular filtration from kidney and taken up into cell by endocytosis.
In this 76 study, we can evaluate the effect of hypothermia on these transporter activities and 77 transport process using PSP, ICG and FD-4.
In the present study, we examined the 78 effect of temperature on hepatic disposition of three model compounds, PSP, ICG and 79 FD-4 by isolated liver perfusion system to exclusive of another factor affecting the 80 hepatic disposition, such as flow rate. 81 82
Materials 84
Phenolsulfonphthalein and indocyanine green were purchased from Nacalai 85 Tesque, Inc. (Kyoto, Japan) and Daiichi Sankyo Pharmaceutical Co., Ltd. (Tokyo, 86 6 started immediately. The inferior vena cava was catheterized through the right atrium 107 with a polyethylene tube (i.d. 1.7 mm, o.d. 2.7 mm, Hibiki, Tokyo, Japan) and then 108 ligated right above the renal vein.
The perfusate was circulated using a peristaltic 109 pump (SJ1211, ATTO Co., Tokyo, Japan) at a flow rate of 13.0 ± 0.2 mL/min (mean ± 110 S.D.).
The experiments at low temperature were carried out with the perfusate 111 maintained at 32 o C or 28 o C. To avoid the effect of interaction with albumin and 112 simplify the perfusion system, liver perfusion was carried out with albumin-free 113 perfusate. 114
After a stabilization period of 30 min, the drug solution (0.1 mL) was injected 115 into the perfusion route.
After administration of the drug solution, venous outflow 116 samples were collected into tubes at appropriate time intervals for 1 min.
The 117 sampling interval was 1 sec at first and gradually prolonged.
Bile samples were 118 collected into weighed test tubes at 5 min for 60 min. The bile sample volumes were 119 calculated from the gain in weight in the test tube assuming the density of the bile to be 120 1.0. The sampling time was taken as the midpoint of the sampling period. After 121 the perfusion experiment, the whole liver was excised and weighed.
The mean 122 weight of the liver was 9.1 ± 0.9 g. 123
124
Assay 125
The concentration of model compounds in the venous outflow perfusate and 126 bile sample was determined as follows.
The concentration of free PSP was 127 determined spectrophotometrically at 560 nm after dilution with 1 M NaOH.
In the 128 case of bile sample, the total concentration of free PSP and its conjugate was measured 129 in the same manner after the samples were subjected to acid hydrolysis (1 M HCl at 7 100 o C for 30 min) (10). The concentration of PSP conjugate was estimated from the 131 difference between these values. 132
The concentration of ICG was determined spectrophotometrically at 805 nm 133 after proper dilution with saline containing 0.1% (w/v) bovine serum albumin as a 134 stabilizer. 135
The concentration of FD-4 was determined spectrophotofluorometrically at 136 excitation and emission wavelengths of 489 and 515 nm, respectively. 137 138
Pharmacokinetic analysis of outflow patterns and biliary excretion rate-time 139
curves 140
The first two (zeroth to first) moments for the outflow pattern are defined as 141 follows: 142
where t is the time and C is the concentration of substances normalized by the injection 145 dose as the percentage of the dose per milliliter, and auc and t are the area under the 146 concentration-time curve and mean transit time, respectively.
The moments were 147 calculated by numerical integration using a linear trapezoidal formula and extrapolation 148 to infinite time based on a monoexponential equation (11).
We chose two 149 representative parameters, apparent distribution volume (V) and hepatic extraction ratio 150 (Eh), to assess local drug disposition. These parameters were derived from moments 151 described previously (12) as follows: 152
Where Q is flow rate of perfusate and F is the recovery ratio. 156
The biliary excretion rate-time curves of free and conjugated PSP were 157 analyzed independently based on the statistical moment theory (11).
In the case of 158 ICG, a biliary recovery ratio (Fb,free) was determined, because the biliary excretion 159 rate-time curve was not appropriate for the monoexponential extrapolation due to 160 incomplete biliary excretion.
Biliary moment parameters for FD-4 were not 161 calculated because of biliary excretion. 162
Biliary moment parameters are defined as follows: 163
where t is the time, and dXb,free/dt and dXb,conj/dt are the biliary excretion rates of free 170 and conjugated PSP, respectively.
The values of dXb,free/dt and dXb,conj/dt are 171 normalized with the injected dose per mL. Fb,free and Fb,conj are the biliary recovery 172 ratios of free and conjugated PSP, respectively. Table 1 lists the moment and disposition parameters for the outflow 188 patterns. The outflow peak concentration of free PSP increased according to the 189 decrease in the perfusion temperature (Fig. 1) , and auc increased to about 1.4 times that 190 of the control condition, respectively, at perfusion temperatures of 32 o C and 28 o C (Table  191 1). The Eh of PSP was significantly decreased in the low perfusion temperature group 192 compared to control, and V of PSP was also decreased according to the perfusion 193 temperature. temperatures. Similar to the change in Eh, the maximum biliary excretion rates of 197 free PSP and its conjugate decreased according to the perfusion temperature. Table 2  198 lists the moment parameters for the biliary excretion rate of free PSP and its conjugate 199 under the different perfusion temperatures. The biliary excretion rates in 60 min for 200 free PSP (Fb,free) and its conjugate (Fb,conj) in the low perfusion temperature group were 201 decreased to about 50% of the control (Table 2 ).
In addition, the 1 and 4) .
It was thus clarified that hepatic extraction 211 of ICG was almost 100% even at low perfusion temperatures. 212 The perfusion can be done independently of the influence of other 232 organ systems, plasma constituents and neural-hormonal effects.
Compared with 233 other in vitro models, however, the hepatic architecture, cell polarity and bile-forming 234 capacity are preserved in the liver perfusion system. 235 PSP, a hydrophilic dye (organic anion), has been clinically used to test renal 236 function in humans, and is excreted into the bile and urine as a free form or conjugative 237 metabolite in rats (10). PSP is known to be taken up by organic anion transporter 238 (OAT) (13) and excreted into bile via multidrug resistance associated protein2 (Mrp2) 239 (14).
In the rat liver perfusion of PSP, Eh and V were significantly decreased by 40% 240 at 28 o C compared to the control condition. The decrease of V was caused by the 241 alternation of auc because the V was calculated by auc and t (Eq. 3, 4) and then the 242 auc of PSP was increased under hypothermia while the t did not change (Table 1) . 243
In this study analyzed based on moment theory, we cannot evaluate the effect of 244 hypothermia on influx and efflux process individually.
However, the increase of auc 245 under hypothermia might be influenced by alternation of influx process because the 246 peak concentration of PSP was increased (Fig 1) . 247
Moreover, we analyzed the biliary excretion of free and conjugated PSP in 248 terms of metabolism in the hepatocytes and secretion from the hepatocytes into the bile. 249
These processes were characterized by the biliary recovery ratio (Fb,free, Fb,conj) and 250 biliary mean transit time ( free b t , , conj b t , ). The biliary mean transit times of free and 251 conjugated PSP were calculated to be 13.3 and 18.8 min and significantly prolonged 252 under hypothermia, respectively (Table 2) .
In a previous study (8), the biliary and 253 metabolic clearance of PSP were reduced under hypothermic conditions in vivo, 254 correlating with the decreasing ratio of Fb,free and Fb,conj in the rat liver perfusion system. 255
In addition, Fb,free/Fb,conj of PSP was not altered at 32 o C while it was increased at 28 o C, 256
suggesting that the conjugation of PSP by enzymes was decreased at 28 o C. Because 257 the drugs conjugated to glucronic acid is excreted into bile via Mrp2, the biliary 258 excretion of these drugs could decreased during hypothermia in clinical. 259 ICG has been widely used as a diagnostic drug to evaluate liver function, 260
especially hepatic blood flow.
The characteristics of ICG are an intravascular 261 distribution, a good capacity to bind blood protein, and excretion into the bile without 262 biotransformation (15,16) via multidrug resistance P-glycoprotein2 (Mdr2) (17). As 263 listed in Table 1 , the Eh of ICG was not affected by the perfusion temperature. 264
Elimination of drugs such as ICG with a high intrinsic hepatic clearance depends largely 265 upon hepatic blood flow, whereas the clearance of drugs such as PSP with an 266 intermediate or low hepatic extraction ratio is much less dependent on alterations in the 267 hepatic blood flow.
In a previous study (8), we clarified that total body clearance 268 (CLtot) of ICG was markedly decreased under hypothermic condition in the rat in vivo, 269 according to body temperature. These results suggest that the decrease of hepatic 270 blood flow was the changing factor of drugs with a high hepatic extraction ratio under 271 hypothermic conditions. 272
The cumulative biliary excretion of ICG in 60 min decreased considerably with 273 the decrease in perfusion temperature (Fig. 3B) .
The reduction in biliary excretion 274 was likely another factor causing the decrease in CLtot. The transepitherial transport temperatures in vitro using LLC-GA5-COL150 cells that expressed human 277 P-glycoprotein specifically on the apical surface showed a multidrug resistant 278 phenotype. (18).
According to this study, MDR1-mediated transport of digoxin 279 decreased at lower temperatures. ICG was excreted into bile by Mdr2, which is one of 280 the ABC transporters, so the decrease in biliary excretion at low perfusate temperatures 281 would be caused by changes in Mdr2 activity.
If the Mdr2 activity could decreased 282 under hypothermia, the pharmacokinetics of digoxin and verapamil, which is substrate 283 of Mdr2, might differ during hypothermia.
Furthermore, the reduction of ICG 284 excretion into bile under hypothermia was larger than that of PSP.
This result 285
suggests that the effect of hypothermia on Mdr2 might be greater than that on Mrp2. 286
However, further studies are necessary for us to investigate the effect of hypothermia on 287 ABC transporter activity by in vitro experiment. 288 FD-4 is excreted mainly by glomerular filtration, and the contribution of 289 hepatic extraction is very low. (19) (20) (21) We used FD-4 as a vascular reference in the 290 rat liver perfusion study.
It was reported that distribution volume of 131 I-human 291 serum albumin, another vascular reference substance, was not changed at 27 o C, 292 compared to 37 o C. (12)
The auc and V were not changed under the low perfusion 293 temperatures.
It was thus indicated that the distribution of FD-4 in the liver was not 294 affected by perfusion temperature. 295
The Eh of FD-4 was significantly decreased at 28 o C compared to 37 o C, while 296 there was no change at 32 o C, suggesting that the elimination of FD-4 by hepatic uptake 297 leading to endocytosis was slightly decreased by the perfusion temperatures.
In case 298 of FD-4, the prolongation of outflow pattern might be caused by slightly release of the 299 FD-4 associated with the liver. Moreover, the t of FD-4 was larger than that of PSP, it probably because of the difference in hepatic disposition between FD-4 and PSP. 301
In the in vivo study (8) 
